Bone Biologics Reports Q2 2025 Financial Results with Net Loss of $740,519

Bone Biologics Corporation has reported its financial results for the second quarter of 2025, revealing a net loss of $740,519, a decrease from a loss of $783,733 in the same period last year. The company did not generate any revenue during the quarter, consistent with its previous fiscal periods. Total operating expenses for the quarter were $748,075, down 7.6% from $809,665 in the prior year, primarily due to a significant reduction in research and development costs, which fell by 45.3% to $191,608. General and administrative expenses, however, increased by 21.2% to $556,467, attributed to the timing of stock option compensation.

For the six months ending June 30, 2025, Bone Biologics reported a net loss of $1,757,611, compared to a loss of $1,649,703 for the same period in 2024. Total operating expenses rose by 4.3% to $1,786,563, with research and development costs increasing slightly to $615,186. The company’s cash position improved significantly, with cash and cash equivalents totaling $6.64 million as of June 30, 2025, compared to $3.33 million at the end of 2024. This increase was bolstered by financing activities, including a public offering that generated net proceeds of $4.35 million.

In terms of strategic developments, Bone Biologics executed a 1-for-6 reverse stock split effective June 10, 2025, aimed at regaining compliance with Nasdaq listing requirements. The company also successfully completed a public offering on June 27, 2025, issuing 793,750 shares of common stock and pre-funded warrants, alongside additional warrants. This offering is expected to provide sufficient capital to fund operations into the second quarter of 2026.

Operationally, Bone Biologics is focused on advancing its lead product, NELL-1/DBM, which is currently undergoing a multicenter, prospective, randomized pilot clinical study in Australia. The study aims to evaluate the safety and effectiveness of the NB1 bone graft device in spinal fusion surgeries. The company has entered into various agreements with contract research organizations to support this clinical trial, which is a critical step toward potential commercialization.

Looking ahead, Bone Biologics anticipates continued investment in research and development as it prepares for pivotal clinical studies. However, the company acknowledges substantial doubt regarding its ability to continue as a going concern, given its accumulated losses of approximately $86.8 million since inception. The management is actively seeking additional financing to support ongoing operations and product development, although there are no assurances that such financing will be secured on favorable terms.